Longview Partners Guernsey LTD increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 6.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,027,808 shares of the medical equipment provider’s stock after acquiring an additional 521,124 shares during the period. Zimmer Biomet makes up approximately 5.1% of Longview Partners Guernsey LTD’s investment portfolio, making the stock its 9th biggest position. Longview Partners Guernsey LTD’s holdings in Zimmer Biomet were worth $968,716,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Private Advisor Group LLC boosted its holdings in shares of Zimmer Biomet by 18.6% in the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock valued at $791,000 after acquiring an additional 1,057 shares in the last quarter. Ingalls & Snyder LLC boosted its holdings in Zimmer Biomet by 2.6% during the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after buying an additional 507 shares in the last quarter. Koch Industries Inc. boosted its holdings in Zimmer Biomet by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after buying an additional 1,038,674 shares in the last quarter. Jana Partners LLC boosted its holdings in Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Zimmer Biomet by 10.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after buying an additional 1,494 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $115.53 on Friday. Zimmer Biomet Holdings Inc has a 52 week low of $108.03 and a 52 week high of $133.49. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. The company has a market cap of $23,390.00, a P/E ratio of 12.81, a P/E/G ratio of 2.12 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting analysts’ consensus estimates of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The firm had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter last year, the business posted $2.14 EPS. The company’s revenue was up 3.0% on a year-over-year basis. analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is 10.64%.

ZBH has been the subject of a number of research reports. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a report on Tuesday, November 14th. Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, November 20th. Canaccord Genuity restated a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet in a report on Tuesday, December 19th. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 target price for the company in a report on Tuesday, December 19th. Finally, Oppenheimer restated a “buy” rating on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $141.67.

COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet Holdings Inc (ZBH) Shares Bought by Longview Partners Guernsey LTD” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/02/09/zimmer-biomet-holdings-inc-zbh-shares-bought-by-longview-partners-guernsey-ltd.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.